ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INCY Incyte Corporation

53.06
-0.44 (-0.82%)
11 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Incyte Corporation NASDAQ:INCY NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.44 -0.82% 53.06 52.16 55.00 53.6725 52.81 53.39 1,505,329 05:00:11

Incyte to Report Fourth Quarter and Year-End 2023 Financial Results

23/01/2024 1:00pm

Business Wire


Incyte (NASDAQ:INCY)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Incyte Charts.

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024.

The schedule for the press release and conference call/webcast is as follows:

  • Q4 & YE 2023 Press Release: February 13, 2024 at 7:00 a.m. ET
  • Q4 & YE 2023 Conference Call: February 13, 2024 at 8:00 a.m. ET
  • Domestic Dial-In Number: 877-407-3042
  • International Dial-In Number: 201-389-0864
  • Conference ID Number: 13744020

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13744020.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, Twitter, Instagram, Facebook, YouTube.

Incyte Contacts Media media@incyte.com

Investors ir@incyte.com

1 Year Incyte Chart

1 Year Incyte Chart

1 Month Incyte Chart

1 Month Incyte Chart

Your Recent History

Delayed Upgrade Clock